Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, Hieken TJ, Izar B, Johnson DB, Kulkarni RP, Luke JJ, Mitchell TC, Mooradian MJ, Rubin KM, Salama AK, Shirai K, Taube JM, Tawbi HA, Tolley JK, Valdueza C, Weiss SA, Wong MK, Sullivan RJ. Pavlick AC, et al. Among authors: sullivan rj. J Immunother Cancer. 2023 Oct;11(10):e006947. doi: 10.1136/jitc-2023-006947. J Immunother Cancer. 2023. PMID: 37852736 Free PMC article.
Ipilimumab for patients with advanced mucosal melanoma.
Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Postow MA, et al. Among authors: sullivan rj. Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28. Oncologist. 2013. PMID: 23716015 Free PMC article.
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Luke JJ, et al. Among authors: sullivan rj. Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2. Cancer. 2013. PMID: 23913718 Free PMC article.
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.
Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Panka DJ, et al. Among authors: sullivan rj. Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15. Mol Cancer Ther. 2014. PMID: 25319388 Free PMC article.
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Carvajal RD, et al. Among authors: sullivan rj. Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18. Clin Cancer Res. 2015. PMID: 25695690 Free PMC article. Clinical Trial.
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.
Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Johnson DB, et al. Among authors: sullivan rj. Cancer Immunol Res. 2015 Mar;3(3):288-295. doi: 10.1158/2326-6066.CIR-14-0207. Cancer Immunol Res. 2015. PMID: 25736262 Free PMC article.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Johnson DB, et al. Among authors: sullivan rj. JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368. JAMA Oncol. 2016. PMID: 26633184
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. Johnson DB, et al. Among authors: sullivan rj. Nat Commun. 2016 Jan 29;7:10582. doi: 10.1038/ncomms10582. Nat Commun. 2016. PMID: 26822383 Free PMC article.
432 results